This summary is generated by an algorithm. If you find any mistakes, let us know.

Advanced Materials Health Care Medical Device North America

VenoStent Raises $2.3M Seed Funding

– VenoStent, an advanced materials company, today announced $2.3 million in seed funding.
– The company leverages its unique polymer engineering technology to develop bioresorbable slip-on polymer wraps, called SelfWrap.
– The product is aimed to eliminate vascular surgery failures, at first targeting vascular access surgery required to initiate hemodialysis treatment for end-stage renal disease (ESRD) patients.
Creative Ventures led the round with participation from IAG Capital Partners, C3 Ventures, Olima Ventures, Texas Halo Fund, Cowtown Angels, and SP Investment Fund, among other prominent investors.
– This brings the total funding to date to more than $6 million.

Europe Medical Device

Axis Spine Technologies Raises £2.2M in Funding

– Axis Spine Technologies, a UK-based MedTech startup, closed a £2.2m funding round.
– The funding was led by ACF Investors’ Delta Fund with follow-on investment from Mercia’s EIS funds.
– An angel syndicate led by Simon Cartmell, who has more than 40 years pharmaceutical, biotech and medtech experience, participated.
– The funding will be used to support the launch of the new device in the USA, and also to progress developments of Oblique, Lateral cage implants, as well as a highly differentiated access system.

Europe Health Care Medical Device

AcuSurgical Raises €5.75M in Series A Financing

– AcuSurgical, a Montpellier, France-based company focused on robotic microsurgery, raised €5.75m in Series A financing.
– The round was led by Mérieux Equity Partners (via OMX Europe Venture Fund) and Supernova Invest (via Supernova 2 Fund), with Sofimac Innovation (via Pertinence Invest 2 Fund) and IRDI Capital Investissement (via Irdinov 2 and Inn’Vest PME Occitanie Est Funds) participating.
– The company intends to use the funds to conduct clinical trials and reach regulatory approval with vitreo-retinal surgery as the first indication.

Asia Biotechnology Health Care Medical Device Therapeutics

Gamida Cell Announces $75 Million Financing with Highbridge Capital Management

– Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to developing and commercializing cures for blood cancers and serious hematologic diseases, today announced the sale of $75m of 5.875% exchangeable senior notes due in 2026 (the “notes”) to certain funds managed by Highbridge Capital Management, LLC.
– The proceeds from this sale of notes, together with the net proceeds of Gamida Cell’s sale of $75m of ordinary shares in December 2020, are expected to provide Gamida Cell with sufficient liquidity to fund the company’s operations into the second half of 2022. These capital infusions will be used to support manufacturing, regulatory and commercial development activities for omidubicel and to further the preclinical and clinical development of GDA-201.

Biotechnology Emergency Medicine Europe Health Care Medical Medical Device

Mainstay Medical Receives US$108M Equity Financing

– Mainstay Medical Holdings, a Dublin, Ireland-based medical device company focused on commercializing an innovative implantable restorative neurostimulation system for people with disabling mechanical Chronic Low Back Pain, closed an equity financing of US$108m.
– The round was co-led by new investors Ally Bridge Group and Sofinnova Partners, through its Crossover Fund, and also included a large, global medical device company.
– Key existing investors participating include Sofinnova Partners (Capital Fund), KCK Group and Fountain Healthcare Partners.

Biotechnology Europe Medical Medical Device Pharmaceutical

OSE Immunotherapeutics Enters a Loan Agreement of up to €25 Million with the European Investment Bank

– OSE Immunotherapeutics entered a loan agreement of up to €25 million with the European Investment Bank.
– The loan facility is divided into three tranches including two tranches of €10 million each and a third tranche of €5 million.

Computer Medical Device North America

Hyperfine Raises $90M in Series D Financing

– Hyperfine Research from Guilford, CT is a developer of a portable MR imaging system.
– The company has closed an oversubscribed $90m Series D financing round.

Health Care Medical Medical Device North America

Q’Apel Medical Raises $22M in Funding

– Q’Apel Medical Raises $22M in Funding.
– The round included River Cities Capital, Soleus Capital, and incumbent investor Research Corporation Technologies (RCT).
– The new investment will be used to increase manufacturing capacity, expand product portfolio and add additional head count.

Computer Medical Device North America

Huami Corp Invests $5 Million in Hyperfine Research D Round to Support Accelerated Application of Disruptive MRI Technology

Huami Corp. (NYSE: HMI) has invested $5 million in Hyperfine Research’s D round of funding, which closed on February 3, 2021.
– Huami’s mission is to connect health with technology, developing both consumer and industrial health technologies.
– The company believes its miniaturization engineering expertise dovetails with efforts to miniaturize medical imaging technology which can disrupt the locations, applications and costs of medical imaging.
– Hyperfine Research is pioneering MRI imaging with its portable Swoop system, which received FDA 510(K) clearance in August of 2020.

Biotechnology CRM Europe Health Care Hospital Information Technology Medical Device Robotics

MedLumics closes upsized EUR 18M (21.7M USD) financing round and appoints new Chairman

– MedLumics, a privately held medical device company developing AblaView®, the first optically-guided real-time ablation catheter system for the treatment of Atrial Fibrillation (AF), announced today that it has closed an upsized EUR 18 million (USD 21.7 million) financing round.
– MedLumics’ optical catheter displays lesion creation in real-time providing the physician with direct visual confirmation of conduction tissue denaturation.
– This round was led by Asabys Partners, along with new investors, VI Partners Swiss Innovation and CDTI Innvierte Economía, and existing investors Andera Partners, Caixa Capital Risc and Innogest Capital II.
– MedLumics is now ready to initiate first in-human regulatory clinical studies and automate scalable product manufacturing.

Crunchbase icon

Content report

The following text will be sent to our editors: